Vitamin D3 for Life

Live Enlightened

Article

High-dose vitamin D for post-COVID fatigue and neuropsychiatric symptoms (2024 RCT): Study Summary

Previous related pageEffect of test-and-treat vitamin D supplementation on SARS-CoV-2 vaccine efficacy and immunogenicity (CORONAVIT; Jolliffe et al., 2022): Full Evidence ReviewNext related pageResistance, Recovery and Immune Resilience: Reading the Outcomes
Study at a glance

Could vitamin D help with symptoms after COVID-19?

The researchers asked whether vitamin D could help adults with fatigue, meaning tiredness, or other symptoms after COVID-19. In this trial, 80 adults were assigned by chance to vitamin D or an inactive treatment called a placebo for eight weeks. Neither the participants nor the researchers knew who was receiving which treatment during the trial.

Which symptoms improved with vitamin D in this trial?

Compared with placebo, the vitamin D group had better fatigue scores, fewer anxiety symptoms and better results on one test of thinking and memory. The trial did not find clear differences between groups in sleep quality, depression symptoms, some other thinking tests, or the blood markers of inflammation it measured.

Do these results apply to everyone with symptoms after COVID-19?

The results differed across the symptoms and tests measured. An improvement on one thinking test did not mean that every thinking measure improved. These findings come from 80 adults followed for eight weeks. They do not establish the same effects for everyone with ongoing symptoms after COVID-19.

How much vitamin D did this trial use?

The study used 60,000 international units (IU) of vitamin D each week. This describes the trial’s treatment and is not an instruction about how much an individual should take.

Read the full article below ↓

Study overview

Charoenporn V et al. (2024) tested whether high-dose vitamin D could improve fatigue and neuropsychiatric symptoms in people with post-COVID syndrome. This was an 8-week, double-blind, randomized, placebo-controlled trial published in Psychiatry and Clinical Neurosciences.

What this study shows

In 80 patients with post-COVID fatigue or neuropsychiatric symptoms, weekly vitamin D (60,000 IU) for 8 weeks improved fatigue scores (CFQ-11), reduced anxiety symptoms (DASS-21 anxiety), and improved cognitive test performance (ACE) compared with placebo. Sleep quality (PSQI), depression symptoms (DASS-21 depression), inflammatory markers (IL-6, CRP), and some cognitive measures (TMT) did not show significant between-group differences.

Key details

  • Design: double-blind randomized placebo-controlled trial
  • Participants: 80 adults with post-COVID fatigue or neuropsychiatric symptoms
  • Intervention: vitamin D3 60,000 IU weekly for 8 weeks vs placebo
  • Outcomes measured: fatigue (CFQ-11), mood (DASS-21), sleep quality (PSQI), cognition (ACE, TMT), IL-6, CRP
  • Main finding direction: fatigue improved; anxiety improved; cognition improved; several secondary outcomes showed no clear change vs placebo

Related study page

For sleep-related trial evidence in this library, see: vitamin-d-sleep-quality-trial

Primary source

Effects of an 8-week high-dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post-COVID syndrome: A randomized controlled trial (PubMed)

Related reading

Original sources

Source

Effects of an 8-week high-dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post-COVID syndrome: A randomized controlled trial (PubMed)

Effects of an 8-week high-dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post-COVID syndrome: A randomized controlled trial (PubMed).

Publication details

Effects of an 8-week high-dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post-COVID syndrome: A randomized controlled trial (PubMed)

Read more →